Targeting systemic IL-2 to BCMA CAR-T cells Editorial

  


Authors: Shi, Y.; Sadelain, M.
Title: Targeting systemic IL-2 to BCMA CAR-T cells
Abstract: CAR-T cells are revolutionizing the treatment of cancer and other diseases. A latest iteration in development involves fusion with an antigen-based CAR enhancer to provide low-affinity IL-2 signaling that might limit adverse effects. © Springer Nature America, Inc. 2024.
Keywords: protein phosphorylation; nonhuman; note; binding affinity; phenotype; interleukin 2; multiple myeloma; in vitro study; dasatinib; chimeric antigen receptor; stat5 protein; dna binding motif; cytokine release syndrome; synthetic biology; ruxolitinib; human; article; b cell maturation antigen; chimeric antigen receptor t-cell; internalization (cell); il 2 signaling; immunoglobulin domain
Journal Title: Nature Immunology
Volume: 25
Issue: 11
ISSN: 1529-2908
Publisher: Nature Publishing Group  
Date Published: 2024-11-01
Start Page: 1988
End Page: 1990
Language: English
DOI: 10.1038/s41590-024-01993-9
PUBMED: 39406960
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85207262802&doi=10.1038%2fs41590-024-01993-9&partnerID=40&md5=93c1dcfeeb4cc0a865aeaeaacd8de211
Notes: Note -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Michel W J Sadelain
    583 Sadelain
  2. Yuzhe Shi
    10 Shi
Related MSK Work